Matthew Green, MD
Dermatology · Casper, WYNPI 1629210992
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 35.3% of the total.
Across 88 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$623
- Regeneron Healthcare Solutions, Inc.$207
- Lilly USA, LLC$160
- Johnson & Johnson$148
- Novartis$144
- Sanofi$137
- plus $346 from 11 others
What the payments were for
- Food & beverage$1,764100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $623 |
| Regeneron Healthcare Solutions, Inc. | 8 | $207 |
| Lilly USA, LLC | 8 | $160 |
| Johnson & Johnson | 7 | $148 |
| Novartis | 7 | $144 |
| Sanofi | 6 | $137 |
| Amgen | 6 | $119 |
| Incyte Corporation | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Pfizer | 2 | $25 |
| Biofrontera Inc. | 1 | $25 |
| UCB, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Smith+Nephew | 1 | $19 |
| Mimedx Group, Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $13 |
How this compares
Too few dermatology providers in Wyomingto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 43 | $3,821 |
| Fluocinonide | 53 | $2,526 |
| Doxycycline Hyclate | 34 | $1,297 |
| Triamcinolone Acetonide | 142 | $1,122 |
| Desonide | 17 | $1,072 |
| Clobetasol Propionate | 16 | $860 |
| Ketoconazole | 66 | $723 |
| Metronidazole | 11 | $668 |
| Spironolactone | 39 | $536 |
| Hydroxyzine Hcl | 13 | $125 |
| Minoxidil | 17 | $111 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Casper
- Tyler QuestCasper$2K
- Scott BennionCasper$2K
- Krystal MasseyCheyenne$9K
- Samuel EckerLaramie$3K
- Gregory SeitzCheyenne$2K
- Sandra SurbruggCheyenne$2K
- Melissa RhoadesGillette$2K
- Julie NevilleCheyenne$1K
- Jonathan BakerJackson$1K
- Brittany BakerJackson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.